Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter. This story matters for Finance & Markets readers tracking largecap. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. LargecapNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily largecap signal